Impact of a new assay for measuring serum creatinine levels on carboplatin dosing

American Journal of Health-System Pharmacy

Volumn 69, Issue 13, 2012, Pages 1136-1141

  Murray, Brian ^a   Bates, Jill ^a   Buie, Larry ^a  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CREATININE; PACLITAXEL; PEMETREXED;

ADULT; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIAGNOSTIC TEST ACCURACY STUDY; DILUTION; ENDOMETRIUM CANCER; ENZYME ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HEAD AND NECK CANCER; HUMAN; ISOTOPE DILUTION MASS SPECTROMETRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL PARAMETERS; MEDICAL RECORD REVIEW; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

EID: 84862898520     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110560     Document Type: Article

References (27)

1. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999; 17:409-22. (Pubitemid 29022420)
2. Kondagunta GV, Bacik J, Bajorin D et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol. 2005; 23:9290-4.
3. Williams SD, Birch R, Einhorn LH et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987; 316:1435-40. (Pubitemid 17079090)
4. Turrisi AT 3rd, Kim K, Blum R et al. Twice-daily compared with once-daily thoracic radiotherapy in limited smallcell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999; 340:265-71. (Pubitemid 29063268)
5. Hoskins PJ, Swenerton KD, Pike JA et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol. 2001; 19:4048-53. (Pubitemid 32976691)
6. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecological oncology group study. J Clin Oncol. 2003; 21:3194-200. (Pubitemid 46606249)
7. Smith IE, Evans BD, Gore ME et al. Carboplatin (paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol. 1987; 5:185-9. (Pubitemid 17021597)
8. Rosell R, Gatzemeier U, Betticher DC et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol. 2002; 13:1539-49. (Pubitemid 35331451)
9. Moskowitz CH, Bertino JR, Glassman JR et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol. 1999; 17:3776-85.
10. Kewalramani T, Zelentz AD, Nimer SD et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004; 103:3684-8. (Pubitemid 38596282)
11. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989; 7:1748-56. (Pubitemid 19272848)
12. Cockcroft DW, Gault MH. Prediction of creatine clearance from serum creatinine. Nephron. 1976; 16:31-41.
13. Jelliffe RW. Creatinine clearance: bedside estimate. Ann Intern Med. 1973; 79:604-5.
14. Shord SS, Bressler LR, Radhakrishnan L et al. Evaluation of the modified diet in renal disease equation for calculation of carboplatin dose. Ann Pharmacother. 2009; 43:235-41.
15. Egorin MJ, Van Echo DA, Olman EA et al. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanediarboxylatoplatinum. Cancer Res. 1985; 45:6502-6. (Pubitemid 16224834)
16. Ekhart C, de Jonge ME, Huitema AD et al. Flat dosing of carboplatin is justified in adult patients with normal renal function. Clin Cancer Res. 2006; 12:6502-8. (Pubitemid 44799724)
17. Barr A, O'Cearbhaill R, Griffin D et al. Evaluation of carboplatin dosage based on 4-variable modification of diet in renal disease equation. Ir J Med Sci. 2009; 178:301-7.
18. Nagao S, Fujiwara K, Imafuku N et al. Difference of carboplatin clearance estimated by the Cockcroft-Gault, Jelliffe, modified-Jelliffe, Wright or Chatelut formula. Gynecol Oncol. 2005; 99:327-33.
19. Okamoto H, Nagatomo A, Kunitoh H et al. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae. Cancer Chemother Pharmacol. 1998; 42:307-12.
20. Donahue A, McCune JS, Faucette S et al. Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing. Cancer Chemother Pharmacol. 2001; 47:373-9. (Pubitemid 32397611)
21. De Lemos ML, Hsieh T, Hamata L et al. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies. Gynecol Oncol. 2006; 103:1063-9. (Pubitemid 44821334)
22. Myers GL, Miller WG, Coresh J et al. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem. 2006; 52:5-18. (Pubitemid 43032461)
23. National Kidney Disease Education Program. CKD and drug dosing. http://nkdep.nih.gov/resources/CKD-drug-dosing.shtml (accessed 2012 Apr 18).
24. National Kidney Disease Education Program. GFR calculators. www.nkdep.nih.gov/professionals/gfr-calculators (accessed 2010 Aug 14).
25. University of North Carolina Hospitals. Memorandum #78: change to IDMS calibration for serum and urine creatinine. http://labs.unchealthcare.org/memo- archives/core78.pdf (accessed 2010 Aug 1).
26. Ando M, Minami H, Ando Y et al. Multiinstitutional validation study of carboplatin dosing formula using adjusted serum creatinine level. Clin Cancer Res. 2000; 6:4733-8. (Pubitemid 32110412)
27. Ando M, Minami H, Saka H et al. Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing. Brit J Cancer. 1997; 76:1067-71. (Pubitemid 27434665)